Open Access

miR‑125a‑5p inhibits the expression of NLRP3 by targeting CCL4 in human vascular smooth muscle cells treated with ox‑LDL

  • Authors:
    • Jiawang Wang
    • Qiong Wu
    • Jing Yu
    • Xufen Cao
    • Zesheng Xu
  • View Affiliations

  • Published online on: July 1, 2019     https://doi.org/10.3892/etm.2019.7717
  • Pages: 1645-1652
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Recent findings have revealed that aberrant miR‑125a‑5p expression is involved in the development of atherosclerosis. The present study aimed to investigate the precise mechanism of microRNA (miR)‑125a‑5p in atherosclerosis. Human vascular smooth muscle cells (HVSMCs) were treated with 20 µg/ml oxidized low‑density lipoprotein (ox‑LDL) for 24 h and were employed as in vitro models of atherosclerosis. Reverse transcription quantitative (RT‑qPCR) assays were used to detect miR‑125a‑5p levels. Immunofluorescence analysis was conducted to assess α‑smooth muscle actin (α‑SMA) expression. Western blotting and RT‑qPCR assays were performed to measure the expression levels of NACHT, LRR and PYD domains‑containing protein 3 (NLRP3), apoptosis associated speck‑like protein (ASC), caspase‑1, active interleukin (IL)‑1β and C‑C motif chemokine 4‑like (CCL4). Furthermore, the association between miR‑125a‑5p and CCL4 was assessed using a double luciferase analysis. In addition, VSMCs were transfected with miR‑125a‑5p mimics (30 nM), miR‑125a‑5p inhibitor (100 nM) or small interfering RNA against CCL4 (si‑CCL4, 50 pM), respectively to further investigate the function of miR‑125a‑5p in ox‑LDL‑treated HVSMCs. The present study found that the expression levels of miR‑125a‑5p were significantly downregulated in HVSMCs, whereas the expression levels of α‑SMA, NLRP3, ASC, caspase‑1, IL‑1β and CCL4 were markedly upregulated following ox‑LDL treatment. Overexpression of miR‑125a‑5p in the absence of ox‑LDL treatment decreased NLRP3, IL‑1β and CCL4 expression, whereas inhibition of miR‑125a‑5p exhibited the opposite effects. The results of double luciferase analysis confirmed that CCL4 was a direct target of miR‑125a‑5p. Moreover, transfection of si‑CCL4 into HVSMCs significantly decreased the ox‑LDL‑induced expression of NLRP3, ASC, caspase‑1 and IL‑1β proteins. Taken collectively, the results of the present study suggested that miR‑125a‑5p could negatively regulate the NLRP3 inflammasome by targeting CCL4 in ox‑LDL‑treated HVSMCs. The data provide new insight to the inhibition of atherosclerosis progression.

References

1 

Frostegard J: Immunity, atherosclerosis and cardiovascular disease. BMC Med. 11:1172013. View Article : Google Scholar : PubMed/NCBI

2 

Singh R, Devi S and Gollen R: Role of free radical in atherosclerosis, diabetes and dyslipidaemia: Larger-than-life. Diabetes Metab Res Rev. 31:113–126. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Meijles DN and Pagano PJ: Nox and inflammation in the vascular adventitia. Hypertension. 67:14–19. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Fujii S: Atherosclerosis, chronic inflammation, and thrombosis: In search of the missing link in laboratory medicine. Rinsho Byori. 63:605–611. 2015.(In Japanese). PubMed/NCBI

5 

Chistiakov DA, Orekhov AN and Bobryshev YV: Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf). 214:33–50. 2015. View Article : Google Scholar : PubMed/NCBI

6 

Zhang X, Shao S, Geng H, Yu Y, Wang C, Liu Z, Yu C, Jiang X, Deng Y, Gao L and Zhao J: Expression profiles of six circulating microRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: A clinical study. J Clin Endocrinol Metab. 99:E766–E774. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Hasanov Z, Ruckdeschel T, Konig C, Mogler C, Kapel SS, Korn C, Spegg C, Eichwald V, Wieland M, Appak S and Augustin HG: Endosialin promotes atherosclerosis through phenotypic remodeling of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 37:495–505. 2017. View Article : Google Scholar : PubMed/NCBI

8 

Byon CH, Han T, Wu J and Hui ST: Txnip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout mice. Atherosclerosis. 241:313–321. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Moss EG: MicroRNAs: Hidden in the genome. Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI

10 

Duarte FV, Palmeira CM and Rolo AP: The emerging role of mitomiRs in the pathophysiology of human disease. Adv Exp Med Biol. 888:123–154. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Donaldson CJ, Lao KH and Zeng L: The salient role of microRNAs in atherogenesis. J Mol Cell Cardiol. 122:98–113. 2018. View Article : Google Scholar : PubMed/NCBI

12 

Lucas T, Bonauer A and Dimmeler S: RNA therapeutics in cardiovascular disease. Circ Res. 123:205–220. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Chen M, Li W, Zhang Y and Yang J: MicroRNA-20a protects human aortic endothelial cells from Ox-LDL-induced inflammation through targeting TLR4 and TXNIP signaling. Biomed Pharmacother. 103:191–197. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Hao L, Wang XG, Cheng JD, You SZ, Ma SH, Zhong X, Quan L and Luo B: The up-regulation of endothelin-1 and down-regulation of miRNA-125a-5p, −155, and −199a/b-3p in human atherosclerotic coronary artery. Cardiovasc Pathol. 23:217–223. 2014. View Article : Google Scholar : PubMed/NCBI

15 

He Y, Hara H and Nunez G: Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 41:1012–1021. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Sutterwala FS, Haasken S and Cassel SL: Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 1319:82–95. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

18 

Di X, Tang X and Di X: Montelukast inhibits oxidized low-density lipoproteins (ox-LDL) induced vascular endothelial attachment: An implication for the treatment of atherosclerosis. Biochem Biophys Res Commun. 486:58–62. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Karim MR, Rahman M, Islam K, Mamun AA, Hossain S, Hossain E, Aziz A, Yeasmin F, Agarwal S, Hossain MI, et al: Increases in oxidized low-density lipoprotein and other inflammatory and adhesion molecules with a concomitant decrease in high-density lipoprotein in the individuals exposed to arsenic in Bangladesh. Toxicol Sci. 135:17–25. 2013. View Article : Google Scholar : PubMed/NCBI

20 

Li WL, Hua LG, Qu P, Yan WH, Ming C, Jun YD, Yuan LD and Nan N: NLRP3 inflammasome: A novel link between lipoproteins and atherosclerosis. Arch Med Sci. 12:950–958. 2016. View Article : Google Scholar : PubMed/NCBI

21 

Warnatsch A, Ioannou M, Wang Q and Papayannopoulos V: Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science. 349:316–320. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Eun SY, Ko YS, Park SW, Chang KC and Kim HJ: IL-1β enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release. Vascul Pharmacol. 72:108–117. 2015. View Article : Google Scholar : PubMed/NCBI

23 

Aday AW and Ridker PM: Antiinflammatory therapy in clinical care: The CANTOS trial and beyond. Front Cardiovasc Med. 5:622018. View Article : Google Scholar : PubMed/NCBI

24 

Sun HJ, Ren XS, Xiong XQ, Chen YZ, Zhao MX, Wang JJ, Zhou YB, Han Y, Chen Q, Li YH, et al: NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell Death Dis. 8:e30742017. View Article : Google Scholar : PubMed/NCBI

25 

Zheng SC, Zhu XX, Xue Y, Zhang LH, Zou HJ, Qiu JH and Liu Q: Role of the NLRP3 inflammasome in the transient release of IL-1beta induced by monosodium urate crystals in human fibroblast-like synoviocytes. J Inflamm (Lord). 12:302015. View Article : Google Scholar

26 

Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T and Ando T: Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis. Pathog Dis. 73:ftv0112015. View Article : Google Scholar : PubMed/NCBI

27 

Natalia MA, Alejandro GT, Virginia TJ and Alvarez-Salas LM: MARK1 is a novel target for miR-125a-5p: Implications for cell migration in cervical tumor cells. Microma. 7:54–61. 2018.

28 

Verite J, Janet T, Julian A, Chassaing D, Page G and Paccalin M: Peripheral blood mononuclear cells of Alzheimer's disease patients control CCL4 and CXCL10 levels in a human blood brain barrier model. Curr Alzheimer Res. 14:1215–1228. 2017. View Article : Google Scholar : PubMed/NCBI

29 

Edsfeldt A, Grufman H, Asciutto G, Nitulescu M, Persson A, Nilsson M, Nilsson J and Gonçalves: Circulating cytokines reflect the expression of pro-inflammatory cytokines in atherosclerotic plaques. Atherosclerosis. 241:443–449. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, J., Wu, Q., Yu, J., Cao, X., & Xu, Z. (2019). miR‑125a‑5p inhibits the expression of NLRP3 by targeting CCL4 in human vascular smooth muscle cells treated with ox‑LDL. Experimental and Therapeutic Medicine, 18, 1645-1652. https://doi.org/10.3892/etm.2019.7717
MLA
Wang, J., Wu, Q., Yu, J., Cao, X., Xu, Z."miR‑125a‑5p inhibits the expression of NLRP3 by targeting CCL4 in human vascular smooth muscle cells treated with ox‑LDL". Experimental and Therapeutic Medicine 18.3 (2019): 1645-1652.
Chicago
Wang, J., Wu, Q., Yu, J., Cao, X., Xu, Z."miR‑125a‑5p inhibits the expression of NLRP3 by targeting CCL4 in human vascular smooth muscle cells treated with ox‑LDL". Experimental and Therapeutic Medicine 18, no. 3 (2019): 1645-1652. https://doi.org/10.3892/etm.2019.7717